Cyrus L. Harmon

24.7k citations

16 papers · 207 indexed · h-index 7

Co-authors: Peter J. Kushner David C. Myles Leslie Hodges-Gallagher Geoffrey L. Greene Gabriel A. Mintier Alivelu Irrinki Erin E. McClelland Leah Quintana
Topics: Estrogen and related hormone effects (10 papers)Advanced Breast Cancer Therapies (8 papers)HER2/EGFR in Cancer Research (4 papers)
Cited by: Genetics Oncology Pulmonary and Respiratory Medicine
Journals: Nature Communications Cancer Research Genome Research
Partner nations: United States Poland Germany

In The Last Decade

Cyrus L. Harmon

16 papers receiving 198 citations

Peers

Countries citing papers authored by Cyrus L. Harmon

Since Specialization

Citations

This map shows the geographic impact of Cyrus L. Harmon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cyrus L. Harmon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cyrus L. Harmon more than expected).

Fields of papers citing papers by Cyrus L. Harmon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cyrus L. Harmon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cyrus L. Harmon. The network helps show where Cyrus L. Harmon may publish in the future.

Co-authorship network of co-authors of Cyrus L. Harmon

This figure shows the co-authorship network connecting the top 25 collaborators of Cyrus L. Harmon. A scholar is included among the top collaborators of Cyrus L. Harmon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cyrus L. Harmon. Cyrus L. Harmon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination 2023 ·Molecular Cancer Therapeutics ·(unknown),(unknown),Leslie Hodges-Gallagher,Fabian E. Ortega,(unknown),(unknown),(unknown),(unknown),David Kulp,Gopinath S. Palanisamy,David C. Myles,Peter J. Kushner,Cyrus L. Harmon	21
2	Abstract A044: The discovery of potent KAT6 inhibitors that demonstrate anti-tumor activity in preclinical models of ER+ breast cancer 2023 ·Molecular Cancer Therapeutics ·Gopinath S. Palanisamy,Venkateshappa Chandregowda,(unknown),(unknown),Brian R. Hearn,Girish Daginakatte,(unknown),Dodderi S. Samiulla,Kalisankar Bera,S. Sangeetha,Leena Khare,(unknown),Dirk A. Heerding,(unknown),Cyrus L. Harmon,Susanta Samajdar,Murali Ramachandra,David C. Myles	1
3	Abstract P2-24-07: Combination of complete estrogen receptor antagonist, OP-1250, and CDK4/6 inhibitors enhances tumor suppression and inhibition of cell cycle-related gene expression 2023 ·Cancer Research ·(unknown),Gopinath S. Palanisamy,(unknown),(unknown),William J. Bodell,David Kulp,Peter J. Kushner,Cyrus L. Harmon	4
4	Abstract P1-17-12: Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer 2022 ·Cancer Research ·Manish R. Patel,Carlos Alemany,Zahi Mitri,Della Makower,Virginia F. Borges,Joseph A. Sparano,(unknown),Pamela Klein,Julia Lawrence,Peter J. Kushner,(unknown),Cyrus L. Harmon,David C. Myles,JoAnne Zujewski,Erika Hamilton	17
5	Abstract 5375: Precision run-on sequencing (PRO-seq) analysis of a treatment time course in ER+ breast cancer cell lines reveals the transcriptional changes underlying response to complete estrogen receptor antagonist (CERAN) OP-1250 2022 ·Cancer Research ·(unknown),Caitlin Miller,(unknown),Leslie Hodges-Gallagher,(unknown),(unknown),Peter J. Kushner,David Kulp,Cyrus L. Harmon	1
6	Abstract PS18-16: The complete estrogen receptor antagonist OP-1250 shrinks tumors in xenograft models and has favorable preclinical pharmacokinetic attributes 2021 ·Cancer Research ·Leslie Hodges-Gallagher,(unknown),David C. Myles,Pamela Klein,Jo Anne Zujewski,Cyrus L. Harmon,Peter J. Kushner	3
7	Abstract OT-09-10: A phase I/II open-label, first-in-human, multicenter, dose escalation and dose expansion study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer 2021 ·Cancer Research ·Erika Hamilton,Carlos Alemany,Nancy U. Lin,Pamela Klein,(unknown),Peter J. Kushner,Cyrus L. Harmon,Jo Anne Zujewski,Manish R. Patel	2
8	Abstract LB122: The complete estrogen receptor antagonist (CERAN) OP-1250 shrinks ER+ brain metastases in an intracranial xenograft tumor model expressing mutant ESR1 2021 ·Cancer Research ·Leslie Hodges-Gallagher,(unknown),(unknown),David C. Myles,Pamela Klein,Cyrus L. Harmon,Peter J. Kushner	4
9	OP-1250: A potent orally available complete antagonist of estrogen receptor-mediated signaling that shrinks wild type and mutant breast tumors 2020 ·European Journal of Cancer ·Leslie Hodges-Gallagher,(unknown),David C. Myles,Pamela Klein,J. Zujewski,Cyrus L. Harmon,Peter J. Kushner	7
10	Abstract P5-05-02: Preclinical development of OP-1250, an oral complete estrogen receptor antagonist (CERAN) that shrinks ER-positive breast tumors in xenograft models 2020 ·Cancer Research ·Leslie Hodges-Gallagher,(unknown),David C. Myles,Cyrus L. Harmon,Peter J. Kushner	4
11	Abstract 4376: OP-1250, a complete estrogen receptor antagonist (CERAN) that shrinks estrogen receptor positive tumors and exhibits favorable pharmacokinetics 2020 ·Cancer Research ·Leslie Hodges-Gallagher,Cyrus L. Harmon,(unknown),David C. Myles,Peter J. Kushner	6
12	Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity 2018 ·Nature Communications ·Sean W. Fanning,Leslie Hodges-Gallagher,David C. Myles,(unknown),(unknown),(unknown),(unknown),Cyrus L. Harmon,Geoffrey L. Greene,Peter J. Kushner	41
13	Genoviz Software Development Kit: Java tool kit for building genomics visualization applications 2009 ·BMC Bioinformatics ·Gregg Helt,(unknown),Ed Erwin,Eric Blossom,Steven G. Blanchard,Stephen A. Chervitz,Cyrus L. Harmon,Ann E. Loraine	20
14	Spatial patterns of gene expression in drosophila melanogaster imaginal discs 2007 ·Gerald M. Rubin,Cyrus L. Harmon	1
15	Joint Nonparametric Alignment for Analyzing Spatial Gene Expression Patterns in Drosophila Imaginal Discs 2005 ·Parvez Ahammad,Cyrus L. Harmon,Ann S. Hammonds,Shankar Sastry,Gerald M. Rubin	4
16	A 1.1-Mb Transcript Map of the Hereditary Hemochromatosis Locus 1997 ·Genome Research ·David A. Ruddy,(unknown),Vince Lee,Gabriel A. Mintier,Leah Quintana,(unknown),Nicole C. Meyer,Alivelu Irrinki,Erin E. McClelland,(unknown),Felipa Mapa,Theodore B. Moore,Winston Thomas,Deborah B. Loeb,Cyrus L. Harmon,Zenta Tsuchihashi,Roger K. Wolff,Randall C. Schatzman,John N. Feder	71

About Cyrus L. Harmon

Cyrus L. Harmon is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology, having authored 16 papers that have together received 207 indexed citations. Recurring topics across this work include Estrogen and related hormone effects (10 papers), Advanced Breast Cancer Therapies (8 papers) and HER2/EGFR in Cancer Research (4 papers). The work is most often cited by research in Genetics (73 citations), Oncology (66 citations) and Pulmonary and Respiratory Medicine (62 citations). Cyrus L. Harmon has collaborated with scholars based in United States, Poland and Germany. Frequent co-authors include Peter J. Kushner, David C. Myles, Leslie Hodges-Gallagher, Geoffrey L. Greene, Gabriel A. Mintier, Alivelu Irrinki, Erin E. McClelland, Leah Quintana, Sean W. Fanning and Zenta Tsuchihashi. Their work appears in journals such as Nature Communications, Cancer Research and Genome Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact